Rigel shares are likely to react positively to acquiring a marketed oncology asset with existing revenue. Watch for HSR clearance and sales trajectory updates in subsequent quarters. The deal adds a near-term revenue stream but carries significant upfront and milestone cash obligations.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $32.13entry
- T+1 · 6mo ago 0.00%α +0.00% · $32.13
- T+5 · 6mo ago −11.92%α −10.76% · $28.30
- T+20 · 5mo ago −0.16%α +0.46% · $32.08
- T+60 · 3mo ago +25.02%α +20.59% · $40.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. Rigel will pay $70M upfront, $15M on transition completion, up to $320M in milestones, plus tiered royalties, and reimburse up to $40M in development costs. The deal provides Rigel with a commercial-stage asset, representing a significant pipeline and revenue opportunity.
Key Financial Metrics
Key Facts
- Rigel obtains exclusive worldwide license for VEPPANU (vepdegestrant), an approved ER+/HER2- breast cancer drug.
- Upfront payment of $70 million, plus $15 million upon successful transition completion.
- Up to $320 million in regulatory and sales milestone payments ($60M regulatory, $260M sales).
- Tiered royalties on net sales from mid-teens to mid-twenties percentages.
- Rigel to reimburse licensors up to $40 million for development costs related to transition activities.
- Agreement subject to HSR antitrust waiting period.
Financial Impact
Upfront $70M cash payment (~14% of market cap) plus $15M near-term, $40M development reimbursement, and up to $320M contingent milestones over life of royalty term.
Risk Factors
- Execution risk in transitioning manufacturing and commercial activities from Pfizer.
- Sales of VEPPANU may not meet thresholds to trigger milestones or cover upfront costs.
- Potential integration challenges and dilution from future capital raises to fund payments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000038 |
| Document: 0001034842-26-000038-index.html | 0001034842-26-000038 |
| Document: 0001034842-26-000038.txt | 0001034842-26-000038 |
Track record
12 reports on RIGL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Viewing Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers